The molecules lost NEW COMPOUNDS BINDING AT THE HISTAMINE SITE OF THE NMDA RECEPTOR (NMDA(HA)R)

NMDA receptor ligands have been the target of intensive research for the treatment of psychotic diseases and central nervous system diseases. Our group published the characterization of the NMDA receptor histamine site. We developed modulators for this site, about 500 drugs were tested and we finally have a partial agonist FUBn293 with a nanomolar affinity and also an antagonist ST-579 with a nanomolar affinity. We suggest that agonists at the (NMDA (HA) R) constitute an innovative class of antipsychotics for the treatment of schizophrenia and other neurological or psychiatric disorders.